(FME) Fresenius Medical Care - Overview
Sector: HealthcareIndustry: Medical Care Facilities | Exchange XETRA (Germany) | Currency EUR | Market Cap: 12.888m | Total Return -13.2% in 12m
Stock: Dialysis Services, Medical Devices, Pharmaceuticals, Water Treatment
Total Rating 46
Risk 87
Buy Signal -0.66
| Risk 5d forecast | |
|---|---|
| Volatility | 29.1% |
| Relative Tail Risk | -7.74% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.50 |
| Alpha | -20.80 |
| Character TTM | |
|---|---|
| Beta | 0.326 |
| Beta Downside | 0.252 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.77% |
| CAGR/Max DD | 0.00 |
EPS (Earnings per Share)
Revenue
Description: FME Fresenius Medical Care March 04, 2026
Fresenius Medical Care AG & Co. KGaA (FME) is a German company specializing in dialysis and renal care. It provides services and products globally to individuals with kidney disease.
The company operates in two segments: Care Delivery and Care Enablement. Care Delivery encompasses outpatient dialysis clinics and contracted hospital dialysis services. Care Enablement involves the development, manufacturing, and distribution of dialysis machines, solutions, and related medical products. The healthcare facilities sector is characterized by high regulatory oversight and specialized medical equipment requirements.
FME also offers ancillary services such as laboratory diagnostics, patient support for home dialysis, and renal pharmaceuticals. These services are critical for managing chronic kidney disease, a condition affecting millions worldwide. Further research on ValueRay can provide detailed financial metrics and competitive analysis.
The company distributes its products to various healthcare providers, including dialysis clinics and hospitals, through a combination of direct sales and independent channels.
Headlines to watch out for
- Dialysis service demand grows with aging global population
- Reimbursement rates for dialysis treatments impact profitability
- Regulatory changes in healthcare policy affect operations
- Product innovation in dialysis technology drives market share
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 978.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.67 > 1.0 |
| NWC/Revenue: 8.42% < 20% (prev 11.70%; Δ -3.28% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.68b > Net Income 978.3m |
| Net Debt (12.10b) to EBITDA (3.35b): 3.61 < 3 |
| Current Ratio: 1.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (285.9m) vs 12m ago -2.56% < -2% |
| Gross Margin: 25.62% > 18% (prev 0.25%; Δ 2.54k% > 0.5%) |
| Asset Turnover: 60.80% > 50% (prev 57.61%; Δ 3.19% > 0%) |
| Interest Coverage Ratio: 4.82 > 6 (EBITDA TTM 3.35b / Interest Expense TTM 384.4m) |
Altman Z'' 2.70
| A: 0.05 (Total Current Assets 7.90b - Total Current Liabilities 6.25b) / Total Assets 31.00b |
| B: 0.39 (Retained Earnings 12.21b / Total Assets 31.00b) |
| C: 0.06 (EBIT TTM 1.85b / Avg Total Assets 32.28b) |
| D: 0.65 (Book Value of Equity 10.82b / Total Liabilities 16.72b) |
| Altman-Z'' Score: 2.70 = A |
Beneish M -3.17
| DSRI: 0.79 (Receivables 3.14b/3.92b, Revenue 19.63b/19.34b) |
| GMI: 0.96 (GM 25.62% / 24.60%) |
| AQI: 1.18 (AQ_t 0.65 / AQ_t-1 0.55) |
| SGI: 1.02 (Revenue 19.63b / 19.34b) |
| TATA: -0.05 (NI 978.3m - CFO 2.68b) / TA 31.00b) |
| Beneish M-Score: -3.17 (Cap -4..+1) = AA |
What is the price of FME shares?
As of March 30, 2026, the stock is trading at EUR 38.54 with a total of 747,108 shares traded.
Over the past week, the price has changed by +2.86%, over one month by -2.31%, over three months by -5.10% and over the past year by -13.17%.
Over the past week, the price has changed by +2.86%, over one month by -2.31%, over three months by -5.10% and over the past year by -13.17%.
Is FME a buy, sell or hold?
Fresenius Medical Care has no consensus analysts rating.
What are the forecasts/targets for the FME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.7 | 16% |
| Analysts Target Price | - | - |
FME Fundamental Data Overview March 29, 2026
Market Cap USD = 12.89b (11.17b EUR * 1.1537 EUR.USD)
P/E Trailing = 11.4702
P/E Forward = 8.8652
P/S = 0.5691
P/B = 0.7919
P/EG = 0.7328
Revenue TTM = 19.63b EUR
EBIT TTM = 1.85b EUR
EBITDA TTM = 3.35b EUR
Long Term Debt = 5.69b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.20b EUR (from shortTermDebt, last quarter)
Debt = 13.70b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.10b EUR (from netDebt column, last quarter)
Enterprise Value = 23.15b EUR (11.17b + Debt 13.70b - CCE 1.73b)
Interest Coverage Ratio = 4.82 (Ebit TTM 1.85b / Interest Expense TTM 384.4m)
EV/FCF = 13.11x (Enterprise Value 23.15b / FCF TTM 1.77b)
FCF Yield = 7.63% (FCF TTM 1.77b / Enterprise Value 23.15b)
FCF Margin = 9.00% (FCF TTM 1.77b / Revenue TTM 19.63b)
Net Margin = 4.98% (Net Income TTM 978.3m / Revenue TTM 19.63b)
Gross Margin = 25.62% ((Revenue TTM 19.63b - Cost of Revenue TTM 14.60b) / Revenue TTM)
Gross Margin QoQ = 27.40% (prev 25.43%)
Tobins Q-Ratio = 0.75 (Enterprise Value 23.15b / Total Assets 31.00b)
Interest Expense / Debt = 0.72% (Interest Expense 99.0m / Debt 13.70b)
Taxrate = 20.83% (106.0m / 509.0m)
NOPAT = 1.47b (EBIT 1.85b * (1 - 20.83%))
Current Ratio = 1.26 (Total Current Assets 7.90b / Total Current Liabilities 6.25b)
Debt / Equity = 1.03 (Debt 13.70b / totalStockholderEquity, last quarter 13.31b)
Debt / EBITDA = 3.61 (Net Debt 12.10b / EBITDA 3.35b)
Debt / FCF = 6.85 (Net Debt 12.10b / FCF TTM 1.77b)
Total Stockholder Equity = 13.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.03% (Net Income 978.3m / Total Assets 31.00b)
RoE = 7.26% (Net Income TTM 978.3m / Total Stockholder Equity 13.48b)
RoCE = 9.67% (EBIT 1.85b / Capital Employed (Equity 13.48b + L.T.Debt 5.69b))
RoIC = 7.14% (NOPAT 1.47b / Invested Capital 20.56b)
WACC = 3.52% (E(11.17b)/V(24.87b) * Re(7.13%) + D(13.70b)/V(24.87b) * Rd(0.72%) * (1-Tc(0.21)))
Discount Rate = 7.13% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -81.65 | Cagr: -1.29%
[DCF] Terminal Value 87.08% ; FCFF base≈1.73b ; Y1≈1.87b ; Y5≈2.32b
[DCF] Fair Price = 201.9 (EV 68.48b - Net Debt 12.10b = Equity 56.38b / Shares 279.3m; r=6.0% [WACC]; 5y FCF grow 9.16% → 3.0% )
EPS Correlation: 74.05 | EPS CAGR: 14.77% | SUE: 2.33 | # QB: 1
Revenue Correlation: 30.55 | Revenue CAGR: 2.94% | SUE: 0.34 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.12 | Chg7d=+0.003 | Chg30d=+0.136 | Revisions Net=-1 | Analysts=3
EPS current Year (2026-12-31): EPS=4.02 | Chg7d=+0.002 | Chg30d=-0.060 | Revisions Net=-2 | Growth EPS=-6.0% | Growth Revenue=-0.8%
EPS next Year (2027-12-31): EPS=4.50 | Chg7d=+0.004 | Chg30d=-0.250 | Revisions Net=-7 | Growth EPS=+11.7% | Growth Revenue=+4.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -0.8% (Discount Rate 7.9% - Earnings Yield 8.7%)
[Growth] Growth Spread = +0.8% (Analyst 0.0% - Implied -0.8%)
P/E Trailing = 11.4702
P/E Forward = 8.8652
P/S = 0.5691
P/B = 0.7919
P/EG = 0.7328
Revenue TTM = 19.63b EUR
EBIT TTM = 1.85b EUR
EBITDA TTM = 3.35b EUR
Long Term Debt = 5.69b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.20b EUR (from shortTermDebt, last quarter)
Debt = 13.70b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.10b EUR (from netDebt column, last quarter)
Enterprise Value = 23.15b EUR (11.17b + Debt 13.70b - CCE 1.73b)
Interest Coverage Ratio = 4.82 (Ebit TTM 1.85b / Interest Expense TTM 384.4m)
EV/FCF = 13.11x (Enterprise Value 23.15b / FCF TTM 1.77b)
FCF Yield = 7.63% (FCF TTM 1.77b / Enterprise Value 23.15b)
FCF Margin = 9.00% (FCF TTM 1.77b / Revenue TTM 19.63b)
Net Margin = 4.98% (Net Income TTM 978.3m / Revenue TTM 19.63b)
Gross Margin = 25.62% ((Revenue TTM 19.63b - Cost of Revenue TTM 14.60b) / Revenue TTM)
Gross Margin QoQ = 27.40% (prev 25.43%)
Tobins Q-Ratio = 0.75 (Enterprise Value 23.15b / Total Assets 31.00b)
Interest Expense / Debt = 0.72% (Interest Expense 99.0m / Debt 13.70b)
Taxrate = 20.83% (106.0m / 509.0m)
NOPAT = 1.47b (EBIT 1.85b * (1 - 20.83%))
Current Ratio = 1.26 (Total Current Assets 7.90b / Total Current Liabilities 6.25b)
Debt / Equity = 1.03 (Debt 13.70b / totalStockholderEquity, last quarter 13.31b)
Debt / EBITDA = 3.61 (Net Debt 12.10b / EBITDA 3.35b)
Debt / FCF = 6.85 (Net Debt 12.10b / FCF TTM 1.77b)
Total Stockholder Equity = 13.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.03% (Net Income 978.3m / Total Assets 31.00b)
RoE = 7.26% (Net Income TTM 978.3m / Total Stockholder Equity 13.48b)
RoCE = 9.67% (EBIT 1.85b / Capital Employed (Equity 13.48b + L.T.Debt 5.69b))
RoIC = 7.14% (NOPAT 1.47b / Invested Capital 20.56b)
WACC = 3.52% (E(11.17b)/V(24.87b) * Re(7.13%) + D(13.70b)/V(24.87b) * Rd(0.72%) * (1-Tc(0.21)))
Discount Rate = 7.13% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -81.65 | Cagr: -1.29%
[DCF] Terminal Value 87.08% ; FCFF base≈1.73b ; Y1≈1.87b ; Y5≈2.32b
[DCF] Fair Price = 201.9 (EV 68.48b - Net Debt 12.10b = Equity 56.38b / Shares 279.3m; r=6.0% [WACC]; 5y FCF grow 9.16% → 3.0% )
EPS Correlation: 74.05 | EPS CAGR: 14.77% | SUE: 2.33 | # QB: 1
Revenue Correlation: 30.55 | Revenue CAGR: 2.94% | SUE: 0.34 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.12 | Chg7d=+0.003 | Chg30d=+0.136 | Revisions Net=-1 | Analysts=3
EPS current Year (2026-12-31): EPS=4.02 | Chg7d=+0.002 | Chg30d=-0.060 | Revisions Net=-2 | Growth EPS=-6.0% | Growth Revenue=-0.8%
EPS next Year (2027-12-31): EPS=4.50 | Chg7d=+0.004 | Chg30d=-0.250 | Revisions Net=-7 | Growth EPS=+11.7% | Growth Revenue=+4.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -0.8% (Discount Rate 7.9% - Earnings Yield 8.7%)
[Growth] Growth Spread = +0.8% (Analyst 0.0% - Implied -0.8%)